Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7536.09 | 1.0167 | 1.0297 | 1.1257 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7536.09 | 0.9386 | 0.8905 | 1.1257 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7536.09 | 0.9391 | 0.8915 | 1.1257 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7536.09 | 0.8686 | 0.7647 | 1.1257 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7536.09 | 0.8003 | 0.6410 | 1.1257 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7536.09 | 0.3350 | -0.2429 | 1.1257 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7536.09 | 0.0638 | -0.8266 | 1.1257 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7536.09 | 0.6706 | 0.4023 | 1.1257 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7537.091 | 0.9844 | 0.9845 | 2.0227 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7537.091 | 0.9676 | 0.9677 | 2.0227 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7537.091 | 0.9866 | 0.9867 | 2.0227 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7537.091 | 1.0053 | 1.0052 | 2.0227 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7537.091 | 1.0087 | 1.0086 | 2.0227 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7537.091 | 1.0391 | 1.0383 | 2.0227 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7537.091 | 0.5468 | 0.4839 | 2.0227 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7537.091 | 0.0161 | -0.7406 | 2.0227 | |
| SUM229PE | TNBC | - | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7537.091 | 0.0029 | -0.8881 | 2.0227 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7539.092 | 1.0485 | 1.0789 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7539.092 | 0.9493 | 0.9167 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7539.092 | 0.9576 | 0.9303 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7539.092 | 1.0184 | 1.0301 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7539.092 | 1.0943 | 1.1528 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7539.092 | 0.8842 | 0.8087 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7539.092 | 0.6841 | 0.4663 | 1.2233 | |
| SUM52PE | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7539.092 | 0.2651 | -0.3245 | 1.2233 |